The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature
|
|---|---|
| Published in |
Drug, Healthcare and Patient Safety, September 2013
|
| DOI | 10.2147/dhps.s48640 |
| Pubmed ID | |
| Authors |
Mohammad Nasser, Timothy R Larsen, Barryton Waanbah, Ibrahim Sidiqi, Peter A McCullough |
| Abstract |
Amiodarone is a benzofuran class III antiarrhythmic drug used to treat a wide spectrum of ventricular tachyarrhythmias. The parenteral formulation is prepared in polysorbate 80 diluent. We report an unusual case of acute elevation of aminotransaminase concentrations after the initiation of intravenous amiodarone. An 88-year-old Caucasian female developed acute hepatitis and renal failure after initiating intravenous amiodarone for atrial fibrillation with a rapid ventricular response in the setting of acutely decompensated heart failure and hepatic congestion. Liver transaminases returned to baseline within 7 days after discontinuing the drug. Researchers hypothesized that this type of injury is related to liver ischemia with possible superimposed direct drug toxicity. The CIOMS/RUCAM scale identifies our patient's acute hepatitis as a highly probable adverse drug reaction. Future research is needed to understand the mechanisms by which hyperacute drug toxicity occurs in the setting of impaired hepatic perfusion and venous congestion. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 4 | 17% |
| Other | 2 | 8% |
| Student > Bachelor | 2 | 8% |
| Student > Master | 2 | 8% |
| Student > Ph. D. Student | 2 | 8% |
| Other | 5 | 21% |
| Unknown | 7 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 58% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Agricultural and Biological Sciences | 1 | 4% |
| Nursing and Health Professions | 1 | 4% |
| Unknown | 7 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 September 2013.
All research outputs
#20,011,936
of 25,457,858 outputs
Outputs from Drug, Healthcare and Patient Safety
#128
of 160 outputs
Outputs of similar age
#154,817
of 212,693 outputs
Outputs of similar age from Drug, Healthcare and Patient Safety
#3
of 4 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 160 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.5. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,693 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.